当前位置: 首页 >> 检索结果
301. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss.
作者: Kate Hallsworth.;Gulnar Fattakhova.;Kieren G Hollingsworth.;Christian Thoma.;Sarah Moore.;Roy Taylor.;Christopher P Day.;Michael I Trenell.
来源: Gut. 2011年60卷9期1278-83页
Lifestyle interventions focusing on weight loss remain the cornerstone of non-alcoholic fatty liver disease (NAFLD) management. Despite this, the weight losses achieved in research trials are not easily replicated in the clinic and there is an urgent need for therapies independent of weight loss. Aerobic exercise is not well sustained and the effectiveness of the better tolerated resistance exercise upon liver lipid and mediators of liver lipid has not been assessed.
302. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
作者: Keith Leiper.;Kate Martin.;Anthony Ellis.;Sreedhar Subramanian.;Alastair J Watson.;Steve E Christmas.;Deborah Howarth.;Fiona Campbell.;Jonathan M Rhodes.
来源: Gut. 2011年60卷11期1520-6页
To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).
303. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
作者: Guy E Boeckxstaens.;Hanneke Beaumont.;Jan G Hatlebakk.;Debra G Silberg.;Karin Björck.;Maria Karlsson.;Hans Denison.
来源: Gut. 2011年60卷9期1182-8页
o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy.
304. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
作者: Séverine Vermeire.;Subrata Ghosh.;Julian Panes.;Jens F Dahlerup.;Andreas Luegering.;Jana Sirotiakova.;Ulrike Strauch.;Gary Burgess.;Jacqueline Spanton.;Steven W Martin.;Wojciech Niezychowski.
来源: Gut. 2011年60卷8期1068-75页
Leucocyte migration to gut mucosa, mediated by integrin binding to mucosal addressin cell adhesion molecule (MAdCAM), is a promising target for therapeutic intervention in inflammatory bowel disease. This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659, aimed to explore the safety and preliminary efficacy of this gut-specific mechanism in ulcerative colitis.
305. A randomised trial of sheathed versus standard forceps for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum.
作者: Maneesh Dave.;Laura A Johnson.;Seth T Walk.;Vincent B Young.;Ryan W Stidham.;Meghana N Chaudhary.;Jessica Funnell.;Peter D R Higgins.
来源: Gut. 2011年60卷8期1043-9页
The study of intestinal microbiota has been revolutionised by the use of molecular methods, including terminal restriction fragment length polymorphism (T-RFLP) analysis. Microbiota studies of Crohn's disease patients have examined samples from stool or from the neoterminal ileum with a standard biopsy forceps, which could be contaminated by colonic bacteria when the forceps passes through the colonoscope channel.
306. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
作者: P B Jeppesen.;R Gilroy.;M Pertkiewicz.;J P Allard.;B Messing.;S J O'Keefe.
来源: Gut. 2011年60卷7期902-14页
Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This 24-week placebo-controlled study evaluated the ability of teduglutide to reduce parenteral support in patients with SBS with intestinal failure.
307. Colorectal cancer screening with odour material by canine scent detection.
作者: Hideto Sonoda.;Shunji Kohnoe.;Tetsuro Yamazato.;Yuji Satoh.;Gouki Morizono.;Kentaro Shikata.;Makoto Morita.;Akihiro Watanabe.;Masaru Morita.;Yoshihiro Kakeji.;Fumio Inoue.;Yoshihiko Maehara.
来源: Gut. 2011年60卷6期814-9页
Early detection and early treatment are of vital importance to the successful treatment of various cancers. The development of a novel screening method that is as economical and non-invasive as the faecal occult blood test (FOBT) for early detection of colorectal cancer (CRC) is needed. A study was undertaken using canine scent detection to determine whether odour material can become an effective tool in CRC screening.
308. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.
作者: Jean-François Rahier.;Pavol Papay.;Julia Salleron.;Shaji Sebastian.;Manuela Marzo.;Laurent Peyrin-Biroulet.;Valle Garcia-Sanchez.;Walter Fries.;Dirk P van Asseldonk.;Klaudia Farkas.;Nanne K de Boer.;Taina Sipponen.;Pierre Ellul.;Edouard Louis.;Simon T C Peake.;Uri Kopylov.;Jochen Maul.;Badira Makhoul.;Gionata Fiorino.;Yazdan Yazdanpanah.;Maria Chaparro.; .
来源: Gut. 2011年60卷4期456-62页
Safety data are lacking on influenza vaccination in general and on A (H1N1)v vaccination in particular in patients with inflammatory bowel disease (IBD) receiving immmunomodulators and/or biological therapy.
309. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
作者: George V Papatheodoridis.;Spilios Manolakopoulos.;Giota Touloumi.;Georgia Vourli.;Maria Raptopoulou-Gigi.;Irini Vafiadis-Zoumbouli.;Themistoklis Vasiliadis.;Kostas Mimidis.;Charalambos Gogos.;Ioannis Ketikoglou.;Emanuel K Manesis.; .
来源: Gut. 2011年60卷8期1109-16页
To evaluate the risk and predictors of hepatocellular carcinoma (HCC) in HBeAg-negative chronic hepatitis B patients of the large HEPNET.Greece cohort study who received long-term oral antivirals starting with lamivudine monotherapy.
310. Accuracy of computed tomographic colonography in a nationwide multicentre trial, and its relation to radiologist expertise.
作者: D Heresbach.;M Djabbari.;F Riou.;C Marcus.;A Le Sidaner.;M A Pierredon-Foulogne.;T Ponchon.;M Boudiaf.;J A Seyrig.;H Laumonier.;D Luet.;M Giraud-Cohen.;A L Pelletier.;A Charachon.;F Ramaholimihaso.;P Bouillet.;M Veyrac.;S Ficarelli.;K Vahedi.;J Keruhel.;H Lamouliatte.;C Ridereau-Zins.;Y Bouhnik.;M Tissier.;B Diris.;A M Zagdanski.;J M Josselin.;S Hamonic.;Y Gandon.
来源: Gut. 2011年60卷5期658-65页
Reports on the accuracy of computed tomographic colonography (CTC) mainly involve series from expert institutions. The aims of this study were to assess CTC accuracy in a nationwide population and to relate it to radiologist performance in their initial training.
311. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.
作者: Jane L Benjamin.;Charlotte R H Hedin.;Andreas Koutsoumpas.;Siew C Ng.;Neil E McCarthy.;Ailsa L Hart.;Michael A Kamm.;Jeremy D Sanderson.;Stella C Knight.;Alastair Forbes.;Andrew J Stagg.;Kevin Whelan.;James O Lindsay.
来源: Gut. 2011年60卷7期923-9页
The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.
312. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial.
作者: Frederike G I van Vilsteren.;Roos E Pouw.;Stefan Seewald.;Lorenza Alvarez Herrero.;Carine M T Sondermeijer.;Mike Visser.;Fiebo J W Ten Kate.;Karl C Yu Kim Teng.;Nib Soehendra.;Thomas Rösch.;Bas L A M Weusten.;Jacques J G H M Bergman.
来源: Gut. 2011年60卷6期765-73页
After focal endoscopic resection (ER) of high-grade dysplasia (HGD) or early cancer (EC) in Barrett's oesophagus (BO), eradication of all remaining BO reduces the recurrence risk. The aim of this study was to compare the safety of stepwise radical ER (SRER) versus focal ER followed by radiofrequency ablation (RFA) for complete eradication of BO containing HGD/EC.
313. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
作者: Walter Reinisch.;William J Sandborn.;Daniel W Hommes.;Geert D'Haens.;Stephen Hanauer.;Stefan Schreiber.;Remo Panaccione.;Richard N Fedorak.;Mary Beth Tighe.;Bidan Huang.;Wendy Kampman.;Andreas Lazar.;Roopal Thakkar.
来源: Gut. 2011年60卷6期780-7页
The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the induction of clinical remission in anti-TNF naïve patients with moderately to severely active ulcerative colitis.
314. Diagnostic value of confocal laser endomicroscopy for gastric superficial cancerous lesions.
作者: Wen-Bo Li.;Xiu-Li Zuo.;Chang-Qing Li.;Fang Zuo.;Xiao-Meng Gu.;Tao Yu.;Chuan-Lian Chu.;Ting-Guo Zhang.;Yan-Qing Li.
来源: Gut. 2011年60卷3期299-306页
The identification of gastric superficial cancerous lesions based on conventional white-light endoscopy (WLE) is challenging, and histological analysis remains the 'gold standard' for the final diagnosis. Confocal laser endomicroscopy (CLE) can provide in vivo histological observation without the need for biopsy.
315. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy.
作者: Jonathan Fletcher.;Mohammad H Derakhshan.;Gareth-Rhys Jones.;Angela A Wirz.;Kenneth E L McColl.
来源: Gut. 2011年60卷4期442-8页
In most patients undergoing endoscopy for upper gastrointestinal (GI) symptoms in the Western world, no macroscopic abnormality or evidence of Helicobacter pylori infection is identified. Following this negative investigation, proton pump inhibitor (PPI) therapy is usually prescribed. The aim of this study was to assess the value of such treatment compared with placebo and to identify predictors of response.
316. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial.
作者: Jürgen Pohl.;Arved Schneider.;Hartmut Vogell.;Gerhard Mayer.;Gernot Kaiser.;Christian Ell.
来源: Gut. 2011年60卷4期485-90页
Colonoscopy is the accepted gold standard for detecting colorectal adenomas, but the miss rate, especially for small and flat lesions, remains unacceptably high. The aim of this study was to determine whether enhanced mucosal contrast using pancolonic chromoendoscopy (PCC) allows higher rates of adenoma detection.
317. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study.
作者: Aravind Sugumar.;Michael J Levy.;Terumi Kamisawa.;G J Webster.;Myung-Hwan Kim.;Felicity Enders.;Zahir Amin.;Todd H Baron.;Mike H Chapman.;Nicholas I Church.;Jonathan E Clain.;Naoto Egawa.;Gavin J Johnson.;Kazuichi Okazaki.;Randall K Pearson.;Stephen P Pereira.;Bret T Petersen.;Samantha Read.;Raghuwansh P Sah.;Neomal S Sandanayake.;Naoki Takahashi.;Mark D Topazian.;Kazushige Uchida.;Santhi Swaroop Vege.;Suresh T Chari.
来源: Gut. 2011年60卷5期666-70页
Characteristic pancreatic duct changes on endoscopic retrograde pancreatography (ERP) have been described in autoimmune pancreatitis (AIP). The performance characteristics of ERP to diagnose AIP were determined.
318. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
作者: Margarita Elkjaer.;Mary Shuhaibar.;Johan Burisch.;Yvonne Bailey.;Hanne Scherfig.;Birgit Laugesen.;Søren Avnstrøm.;Ebbe Langholz.;Colm O'Morain.;Elsebeth Lynge.;Pia Munkholm.
来源: Gut. 2010年59卷12期1652-61页
The natural history of ulcerative colitis requires continuous monitoring of medical treatment via frequent outpatient visits. The European health authorities' focus on e-health is increasing. Lack of easy access to inflammatory bowel disease (IBD) clinics, patients' education and understanding of the importance of early treatment at relapse is leading to poor compliance. To overcome these limitations a randomised control trial 'Constant-care' was undertaken in Denmark and Ireland.
319. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
作者: S J Patterson.;J George.;S I Strasser.;A U Lee.;W Sievert.;A J Nicoll.;P V Desmond.;S K Roberts.;S Locarnini.;S Bowden.;P W Angus.
来源: Gut. 2011年60卷2期247-54页
To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV).
320. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production.
作者: Peter J Mannon.;Ronald L Hornung.;Zhiqiong Yang.;Chuli Yi.;Catherine Groden.;Julia Friend.;Michael Yao.;Warren Strober.;Ivan J Fuss.
来源: Gut. 2011年60卷4期449-55页
Ulcerative colitis is associated with increased interleukin 13 (IL-13) production by natural killer T cells. Taking advantage of the inhibitory actions of interferon β on IL-13 expression, this proof-of-concept study aimed to show that decreasing IL-13 production is associated with clinical improvement of ulcerative colitis symptoms.
|